Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804796 | 1.00 | NOS1 (0.40) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL31393062 | 0.81 | NOS1 (0.38) | NOS1AXLIDO1TDO2 | |
| SCHEMBL22805867 | 0.81 | NOS1 (0.38) | NOS1AXLIDO1TDO2 | |
| SCHEMBL29602927 | 0.81 | NOS1 (0.34) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL22806465 | 0.78 | NOS1 (0.35) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL29363726 | 0.78 | NOS1 (0.35) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL23478332 | 0.74 | NOS1 (0.46) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL22489490 | 0.74 | NOS1 (0.38) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL19995841 | 0.74 | NOS1 (0.38) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL30975376 | 0.74 | NOS1 (0.34) | NOS1AXLIDO1TDO2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119173253-A | Combination of allosteric and orthosteric EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113966335-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-113993873-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-114008049-B | EGFR inhibitors for cancer treatment | 豪夫迈·罗氏有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993873-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |